Rethinking target discovery in polygenic diseases

Current Topics in Medicinal Chemistry

Volumn 6, Issue 16, 2006, Pages 1791-1798

  Flordellis, Christodoulos S ^a   Manolis, Antonis S ^b   Paris, Hervé ^c   Karabinis, Andreas ^d  

^a UNIVERSITY OF PATRAS   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c CHU RANGUEIL   (France)

^d KAT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; APTAMER; CLOZAPINE; DOUBLE STRANDED RNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NETAMIFTIDE; NEUROLEPTIC AGENT; NEW DRUG; PROTEIN TYROSINE KINASE; RIBOZYME; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB;

AUTOMATION; BINDING SITE; CLINICAL FEATURE; COMPUTER MODEL; CONSENSUS DEVELOPMENT; DIAGNOSTIC PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ELECTRONICS; ENZYME INHIBITION; FINANCIAL MANAGEMENT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC ASSOCIATION; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME PROJECT; INDIVIDUALIZATION; KNOCKOUT GENE; LIQUID CHROMATOGRAPHY; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PATIENT CARE; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; ROBOTICS; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY; TOXICOGENETICS; VALIDATION STUDY;

ANIMALS; DRUG DESIGN; GENE TARGETING; HUMANS; MULTIFACTORIAL INHERITANCE; TECHNOLOGY, PHARMACEUTICAL;

EID: 33748316566     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606778194226     Document Type: Review

References (59)

1. Knowles, J.; Gromo, G. A guide to drug discovery: Target selection in drug discovery. Nat. Rev. Drug Discov., 2003, 2, 63-69.
2. Service, R. F. Surviving the blockbuster syndrome. Science, 2004, 303, 1796-1799.
3. Booth, B.; Zemmel, R. Prospects for productivity. Nat. Rev. Drug Discov., 2004, 3, 451-456.
4. Schmid, E. F.; Smith, D. A. Keynote review: Is declining innovation in the pharmaceutical industry a myth? Drug Discov. Today, 2005, 10, 1031-1039.
5. Ladner, R. C.; Ley, A. C. Novel frameworks as a source of high-affinity ligands. Curr. Opin. Biotechnol., 2001, 12, 406-410.
6. Lindsay, M. A. Target discovery. Nat. Rev. Drug Discov., 2003, 2, 831-838.
7. Ban, T. A. Neuropsychopharmacology and the genetics of schizophrenia: a history of the diagnosis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004 28, 753-762.
8. Wise, A.; Gearing, K.; Rees, S. Target validation of G-protein coupled receptors. Drug Discov. Today, 2002, 7, 235-246.
9. Yokomizo, T.; Izumi, T.; Chang, K.; Takuwa, Y.; Shimizu, T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature, 1997, 387, 620-624.
10. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1, 727-730.
11. Henning, S. W.; Beste, G. Loss-of-function strategies in drug target validation. Curr. Drug Discov., 2002, 17-21.
12. Flanagan, A.; Guy, P.; Lubkeman, M.; Steiner, M.; Reeves, M.; Tollman, P. A revolution in R&D. The Boston Consulting Group Report, 2002, 26, 1-64.
13. Ilag, L. L.; Ng, J. H.; Beste, G.; Henning, S. W. Emerging high-throughput drug target validation technologies. Drug Discov. Today, 2002, 7, S136-142.
14. Sirois, S.; Hatzakis, G.; Wei, D.; Du, Q.; Chou, K. C. Assessment of chemical libraries for their druggability. Comput. Biol. Chem., 2005, 29, 55-67.
15. Jones, S. W.; Souza, P. M.; Lindsay, M. A. siRNA for gene silencing: a route to drug target discovery. Curr. Opin. Pharmacol., 2004, 4, 522-527.
16. Hannon, G. J. RNA interference. Nature, 2002, 418, 244-251.
17. Sioud, M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol., 2005, 348, 1079-1090.
18. Leung, R. K.; Whittaker, P. A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther., 2005, 107, 222-239.
19. Soutschek, J.; Akinc, A. Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir: S.; Geick, A.; Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.; Lavine, G.; Pandey, R. K.; Racie, T.; Rajeev, K. G.; Rohl, I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.; Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H. P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004, 432, 173-178.
20. Ilag, L. L. Are genomic and proteomic technologies adding value to drug discovery ? Targets, 2002, 1, 153-155.
21. Flordellis, C. S. The emergence of a new paradigm of pharmacogenomics. Pharmacogenomics, 2005, 6, 515-526.
22. Furness, L. M. Analysis of gene and protein expression for drug mode of toxicity. Curr. Opin. Drug Discov. Devel., 2002, 5, 98-103.
23. Fitzgerald, G. A. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics. Nat Rev Drug Discov, 2005, 4, 815-818.
24. Drews, J. Drug discovery: a historical perspective. Science, 2000, 287, 1960-1964.
25. MacCoss, M.; Baillie, T. A. Organic chemistry in drug discovery. Science, 2004, 303, 1810-1813.
26. Williams, M. Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? Biochem. Pharmacol., 2005, 70, 1707-1716.
27. Maudsley, S.; Martin, B.; Luttrell, L. M. The origins of diversity and specificity in g protein-coupled receptor signaling. J. Pharmacol. Exp. Ther., 2005, 314, 485-494.
28. Gershell, L. J.; Atkins, J. H. A brief history of novel drug discovery technologies. Nat. Rev. Drug Discov., 2003, 2, 321-327.
29. Duyk, G. Attrition and translation. Science, 2003, 302, 603-605.
30. Leifert, W. R.; Aloia, A. L.; Bucco, O.; Glatz, R. V.; McMurchie, E. J. G-protein-coupled receptors in drug discovery: nanosizing using cell-free technologies and molecular biology approaches. J. Biomol. Screen., 2005, 10, 765-779.
31. Ma, P.; Zemmel, R. Value of novelty? Nat. Rev. Drug Discov., 2002, 1, 571-572.
32. von Rechenberg, M.; Blake, B. K.; Ho, Y. S.; Zhen, Y.; Chepanoske, C. L.; Richardson, B. E.; Xu, N.; Kery, V. Ampicillin/penicillin-binding protein interactions as a model drug-target system to optimize affinity pull-down and mass spectrometric strategies for target and pathway identification. Proteomics, 2005, 5, 1764-1773.
33. Karin, M. Inflammation-activated protein kinases as targets for drug development. Proc. Am. Thorac. Soc., 2005, 2, 386-390; discussion 394-385.
34. Chen, L. W.; Egan, L.; Li, Z. W.; Greten, F. R.; Kagnoff, M. F.; Karin, M. The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat. Med., 2003, 9, 575-581.
35. Grillone, L. R.; Lanz, R. Fomivirsen. Drugs Today (Barc), 2001, 37, 245-255.
36. Scherer, L. J.; Rossi, J. J. Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol., 2003, 21, 1457-1465.
37. Bridge, A. J.; Pebernard, S.; Ducraux, A.; Nicoulaz, A. L.; Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet., 2003, 34, 263-264.
38. Persengiev, S. P.; Zhu, X.; Green, M. R. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA, 2004, 10, 12-18.
39. Jackson, A. L.; Bartz, S. R.; Schelter, J.; Kobayashi, S. V.; Burchard, J.; Mao, M.; Li, B.; Cavet, G.; Linsley, P. S. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol, 2003, 21, 635-637.
40. Jackson, A. L.; Linsley, P. S. Noise amidst the silence: off-target effects of siRNAs? Trends Genet., 2004, 20, 521-524.
41. Saxena, S.; Jonsson, Z. O.; Dutta, A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J. Biol. Chem., 2003, 278, 44312-44319.
42. Kenakin, T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov., 2005, 4, 919-927.
43. Hyman, S. E.; Fenton, W. S. Medicine. What are the right targets for psychopharmacology? Science, 2003, 299, 350-351.
44. Wilk, C. M.; Gold, J. M.; Humber, K., Dickerson, F.; Fenton, W. S.; Buchanan, R. W. Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr. Res., 2004, 70, 175-186.
45. Fenton, W. S.; Stover, E. L.; Insel, T. R. Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective. Psychopharmacology (Berl). 2003, 169, 365-366.
46. van 't Veer, L. J.; Dai, H.; van de Vijver, M. J.; He, Y. D.; Hart, A. A.; Mao, M.; Peterse, H. L.; van der Kooy, K.; Marton, M. J.; Witteveen, A. T.; Schreiber, G. J.; Kerkhoven, R. M.; Roberts, C.; Linsley, P. S.; Bernards, R.; Friend, S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415, 530-536.
47. Liang, Y.; Diehn, M.; Watson, N.; Bollen, A. W.; Aldape, K. D.; Nicholas, M. K.; Lamborn, K. R.; Berger, M. S.; Botstein, D.; Brown, P. O.; Israel, M. A. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc. Natl. Acad. Sci. USA, 2005, 102, 5814-5819.
48. Siu, L. L.; Awada, A.; Takimoto, C. H.; Piccart, M.; Schwartz, B.; Giannaris, T.; Lathia, C.; Petrenciuc, O.; Moore, M. J. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res., 2006, 12, 144-151.
49. Faivre, S.; Delbaldo, C.; Vera, K.; Robert, C.; Lozahic, S.; Lassau, N.; Bello, C.; Deprimo, S.; Brega, N.; Massimini, G.; Armand, J. P.; Scigalla, P.; Raymond, E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol., 2006, 24, 25-35.
50. Flordellis, C. S.; Ilias, I.; Papavassiliou, A. G. New therapeutic options for the metabolic syndrome: what's next? Trends Endocrinol. Metab., 2005, 16, 254-260.
51. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov., 2004, 3, 353-359.
52. Stephenson, V. C.; Heyding, R. A.; Weaver, D. F. The "promiscuous drug concept" with applications to Alzheimer's disease. FEBS Lett., 2005, 579, 1338-1342.
53. Espinoza-Fonseca, L. M. The benefits of the multi-target approach in drug design and discovery. Bioorg. Med. Chem., 2006, 14, 896-897.
54. Palfreyman, M. G.; Hook, D. J.; Klimczak, L. J.; Brockman, J. A.; Evans, D. M.; Altar, C. A. Novel directions in antipsychotic target identification using gene arrays. Curr. Drug Targets CNS Neurol. Disord., 2002, 1, 227-238.
55. Brunner, D.; Nestler, E.; Leahy, E. In need of high-throughput behavioral systems. Drug Discov. Today, 2002, 7, S107-112.
56. Reidhaar-Olson, J. F.; Braxenthaler, M.; Hammer, J. Process Biology: Integrated genomics and bioinformatics tools for improved targetb assessment. Targets, 2002, 1, 189-195.
57. Sams-Dodd, F. Optimizing the discovery organization for innovation. Drug Discov. Today, 2005, 10, 1049-1056.
58. Hardy, L. W.; Peet, N. P. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. Drug Discov. Today, 2004, 9, 117-126.
59. Yamada, M.; Lamping, K. G.; Duttaroy, A.; Zhang, W.; Cui, Y.; Bymaster, F. P.; McKinzie, D. L.; Felder, C. C., Deng, C. X.; Faraci, F. M.; Wess, J. Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. USA, 2001, 98, 14096-14101.